The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Early versus delayed autologous stem cell transplant (ASCT) in patients receiving induction therapy with lenalidomide, bortezomib, and dexamethasone (RVD) for newly diagnosed multiple myeloma (MM).
Ajay K. Nooka
No relevant relationships to disclose
Amelia A. Langston
No relevant relationships to disclose
Edmund K. Waller
No relevant relationships to disclose
Leonard T. Heffner
No relevant relationships to disclose
Charise Gleason
No relevant relationships to disclose
Samatha Muppidi
No relevant relationships to disclose
Melanie Watson
No relevant relationships to disclose
Daniela Casbourne
No relevant relationships to disclose
Lawrence Boise
Consultant or Advisory Role - Onyx
Jonathan L. Kaufman
Consultant or Advisory Role - Celgene; Janssen; Millennium; Novartis; Onyx
Research Funding - Celgene; Merck
Sagar Lonial
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; Johnson & Johnson; Millennium; Novartis; Onyx; Sanofi